Constronics Infra Ltd.
Snapshot View

View in App

Prices View details

5.05 ▼0%

19 May 2022, 04:01:00 PM

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.constronicsinfra.com
Market Cap 3.64 Cr.
Enterprise Value(EV) 4.56 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 0.04 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 117.44 Trailing Twelve Months Ending 2021-12
Industry PE 41.03 Trailing Twelve Months Ending 2021-12
Book Value / Share 0.07 Trailing Twelve Months Ending 2021-12
Price to Book Value 69.75 Calculated using Price: 5.05
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 0.72 Cr. 7,209,041 Shares
FaceValue 10
Company Profile

Invicta Meditek Limited (Invicta) incorporated in 1992 is a Public Limited company engaged in the manufacture of quality Orthopaedic Implants and Instruments.

Invicta Meditek manufacture the quality Orthopaedic Implants and Instruments. Invicta serves the field of Orthopaedics by supplying products for Total Joint Replacement systems, Trauma Implants and Associated Instruments. The product range also includes implants for Hemi-Arthroplasty, all types of Dynamic Compression and round hole plates, Screws with Cortical, Cancellous profiles, special thread sizes and in all diameters (with and without cannulation) and DHS/ DCS systems. The Joint Replacement Systems for Knee, Hip, Shoulder and Ankle are manufactured under license from Endotec Inc., USA.

Invicta has established a full-fledged machine shop with sophisticated, state of the art machinery required to meet the challenging, stringent quality requirements of the Orthopaedic implants and the high levels of accuracy required for the instruments used in joint replacement and other critical surgical operations.

Invicta lays special emphasis on achieving customer satisfaction by demonstrating the ability to consistently provide products that meet and exceed customer requirements. The Quality Control Department is equipped with the latest tools and instruments maintaining the strict quality standards demanded by the orthopaedic community.

Invicta’s product portfolio includes:-Total Joint Replacements for Knee, Hip, Ankle, Shoulder (under license from Endotec Inc., USA) -trauma implants (plates, screws, nails etc) -associated instrumentation

Product range of the company includes:

  • BP Hiflex Knee
  • Hip Implants
  • Trauma Implants
  • Conventional Implants
  • Instruments

Achievements/ recognition :

  • It is an ISO 13485-2003 & CE certified company.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
-4.90%
1 Month
-47.56%
3 Month
-47.56%
6 Month
-45.05%
1 Year
+3.06%
2 Year
+15.03%
5 Year
+29.49%
10 Year
-75.25%

Ratios View Details

9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) -6.86 -6.88 -10.77 -12.17 -14.42 -42.43 -171.88 192.41 -138.75
Return on Capital Employed (%) -6.80 -6.78 -10.74 -12.13 -14.10 -20.15 -2.97 11.11 -9.14
Return on Assets (%) -4.86 -4.10 -5.95 -6.02 -6.25 -11.92 -2.40 8.89 -8.66

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 1 1 1 1 1 0 0 0 0
Non Curr. Liab. 1 0 0 0
Curr. Liab. 1 1 1 1 1 0 1 1 1 2
Minority Int.
Equity & Liab. 1 1 1 1 1 1 1 1 1 2
Non Curr. Assets 0 0 0 0 0 1 1 1 1 1
Curr. Assets 1 1 1 1 1 0 0 0 0 1
Misc. Exp. not W/O
Total Assets 1 1 1 1 1 1 1 1 1 2

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 1 2 2 2
Other Income 0 0 0
Total Income 0 1 2 2 2
Total Expenditure 0 0 0 0 0 0 -1 -2 -2 -2
PBIDT 0 0 0 0 0 0 0 0 0 0
Interest
Depreciation 0
Taxation
Exceptional Items
PAT 0 0 0 0 0 0 0 0 0 0
Adjusted EPS 0 0 0 0 0 0 0 0 0 0

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 0 0 0 0 0 0 0
Cash Fr. Inv.
Cash Fr. Finan. 0 0 0
Net Change 0 0 0 0 0 0
Cash & Cash Eqvt 0 0 0 0 0

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 16.58 16.58 16.58 16.58 16.58 18.47 18.47 18.47 18.47
Public 83.42 83.42 83.42 83.42 83.42 81.53 81.53 81.53 81.53
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Sat, 21 May 2022
Board Meeting Intimation for Intimation Under Regulation 30 Of SEBI(LODR) Regulations 2015
Constronics Infra Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2022 inter alia to consider and approve With reference to above we wish to inform you that the meeting of the Board of Directors of the Company will be held on Saturday 28th May 2022 at 11.00 AM at registered office of the company to transact the following businesses:1. To consider and approve the Audited financial results for the quarter and year ended 31st March 20222. Any other businesses with the permission of the Chairman.
Fri, 13 May 2022
Voting Results And Scrutinizer''s Report Of The Extra Ordinary General Meeting Of The Company Held On Wednesday The 11Th Day Of May 2022
Pursuant to Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform that the Extra Ordinary General Meeting of the Company was duly held on Wednesday the 11th day of May 2022 at 9.30 PM (1ST) at registered office of the Company situated at No. 3/2 Third Floor Narasimmapuram Sai Baba Colony Mylapore Chennai - 600 004 and the business mentioned in the Notice convening the EGM were transacted. We herewith enclosed the following documents for your reference and records:1. The Voting Results of the business transacted at the Extra Ordinary General Meeting of the Company as required under Regulation 44 of the SEBI Listing Regulations.2. Report of the Scrutinizer dated May 12 2022 pursuant to Section 108 of the Companies Act 2013 and Rule 20 of the Companies (Management and Administration) Rules 2014.Kindly take the above on record
Fri, 13 May 2022
Disclosure of Voting results of EGM (Regulation 44(3) of SEBI (LODR) Regulations 2015)
Constronics Infra Ltd has informed BSE regarding the details of Voting results of EGM under Regulation 44(3) of SEBI (LODR) Regulations 2015. Kindly Click here

Technical Scans View Details

Thu, 19 May 2022
Close Crossing Last Week Low Close Crossing Last Week Low
Opening at High Opening at High
Opening at Low Opening at Low
Closing Below Previous Low Closing Below Previous Low
Close Within 52 Week Low Zone Close Within 52 Week Low Zone

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%